Efficacy of addition of hrHPV testing by Hybrid Capture II to conventional cytological screening for cervical cancer: 5 years follow-up.
Completed
- Conditions
- Cervical intraepithelial neoplasia (CIN), Cervix cancer
- Registration Number
- NL-OMON21745
- Lead Sponsor
- SALTRO - Doctor Laboratory & Thrombosis Service, VU University Medical Center, Department of Pathology
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50000
Inclusion Criteria
1. Women invited for the cervical cancer screening program (ages 30-60 years);
2. General practitioner affiliated with SALTRO laboratory.
Exclusion Criteria
1. Not called for screening, i.e., ages under 30 years, or over 60 years;
2. Follow-up of previous non-normal cytology within the current screening round of the program, i.e., abnormal cytology or lesion ¡ÝCIN3 less than 2 years before inclusion;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method